June is CAH Awareness Month, a time dedicated to increasing understanding of congenital adrenal hyperplasia (CAH) and supporting the individuals and families impacted by this rare genetic condition. CAH affects the adrenal glands and can interfere with the body’s ability to produce essential hormones, including cortisol and aldosterone. While the condition is rare, early diagnosis and ongoing specialized care can make a significant difference in patient outcomes.
Newborn screening has improved the early identification of the most severe forms of CAH, allowing treatment to begin quickly and helping to prevent life-threatening adrenal crises. However, many patients continue to face challenges related to disease management, treatment burden, transition of care, and quality of life throughout childhood and adulthood.
CAH Awareness Month is also an opportunity to recognize the importance of continued research, multidisciplinary care, patient advocacy, and education within the rare disease community. As treatment approaches evolve, collaboration among healthcare professionals, caregivers, advocacy organizations, and industry partners remains essential to improving long-term outcomes for patients living with CAH.
At CheckRare, we are committed to raising awareness of rare endocrine disorders like CAH and helping connect healthcare professionals and patients with timely educational resources, expert insights, and emerging clinical developments.